Background Conventional cyclophosphamide-based treatment regimens for lupus nephritis (LN) are still not considered to be optimal. The aim of this study was to evaluate the efficacy and safety of mizoribine, tacrolimus, and corticosteroid combination therapy for LN. Methods We retrospectively evaluated a combination treatment of mizoribine and tacrolimus with corticosteroids as induction therapy in eight newly diagnosed systemic lupus erythematosus (SLE) patients with biopsy-proven LN. Results All patients were women, and their mean [standard deviation (SD)] age was 48.5 (20) years. All patients (100 %) had positive anti-double-stranded DNA (antidsDNA) antibody titers, and four (50.0 %) were nephrotic. Mean (SD) serum creatinine and daily proteinuria levels were 0.72 (0.4) mg/dl (range 0.33-1.55 mg/dl) and 4.56 (2.8) g (range 0.77-8.2 g), respectively. By month 2, significant improvements in the anti-dsDNA antibody titers, levels of proteinuria, serum albumin, and C3, and SLE disease activity index score were observed. By month 6, seven patients (87.5 %) were in complete remission, with normalized levels of both proteinuria and serum creatinine. Conclusions This pilot study suggests that mizoribine and tacrolimus treatment with corticosteroids is well tolerated and may prove to be an optimal alternative remissioninducing regimen for LN.
Introduction
Systemic lupus erythematosus (SLE) is a potentially fatal autoimmune disease that involves multiple vital organs. SLE is associated with diverse clinical features that range from rash and arthritis to cytopenia, serositis, nephritis, seizures, and psychosis. Lupus nephritis (LN) is a major manifestation of SLE and has the worst prognosis [1] [2] [3] [4] [5] . As an early response to immunosuppressive therapy is predictive of a good long-term renal outcome [5] [6] [7] , regimens that induce rapid remission are needed. The combination of corticosteroids and cyclophosphamide pulse therapy has been the standard therapy for diffuse proliferative LN. However, a significant number of LN patients (17-57 %) fail to achieve complete or partial remission despite receiving the standard therapy [8] [9] [10] [11] [12] [13] . Only a small percentage of patients (8.1-8.6 %) treated with mycophenolate mofetil (CellCept, MMF) or intravenously administered cyclophosphamide achieved complete remission-strictly defined as return to normal serum creatinine, urine protein B0.5 g/day, and inactive urinary sediment-in a large multinational study [14] . Indeed, the standard therapy for SLE has its limitations because of the heterogeneous disease mechanisms that underlie SLE. Furthermore, in comparison with patients who receive corticosteroids alone, patients receiving cyclophosphamide-based treatment regimens show higher long-term renal survival rates but not higher overall survival rates [11] . The use of cyclophosphamide-based treatment regimens is limited by the potentially severe and toxic adverse effects, which include bone marrow suppression, hemorrhagic cystitis, opportunistic infections, malignant diseases, and premature gonadal failure [8, 15] . As conventional treatments for LN have not provided satisfactory clinical outcomes, alternative treatments are required.
Mizoribine (Bredinin, MZB) is a purine synthesis inhibitor with similar activity to MMF and has been used in Japan for patients undergoing renal transplantation and in patients with rheumatoid arthritis, LN, and nephrotic syndrome [16] [17] [18] [19] [20] [21] [22] . MZB oral pulse therapy has been reported to be of benefit in patients with LN disease flare-up. Furthermore, MZB appears to be safer than cyclophosphamide and other immunosuppressive agents. Tacrolimus (Prograf, FK506) is a T-cell-specific calcineurin inhibitor increasingly used in not only transplant medicine but also autoimmune diseases, such as SLE [23] [24] [25] [26] [27] [28] [29] [30] [31] , rheumatoid arthritis [32] , inflammatory bowel disease, and myasthenia gravis. MMF is a selective inhibitor of B-cell and T-cell proliferation, and a combined therapy comprising administration of steroids, MMF, and FK506, which had been applied for patients undergoing organ transplantation, was successfully used for patients with severe LN [33] . As clinical use of MMF and cyclophosphamide for LN has not yet been approved as a health insurance treatment in Japan, we used a combination regimen of MZB and FK506 with corticosteroids as induction treatment for LN. In this study, we retrospectively evaluated a combination regimen of MZB and FK506 with corticosteroids for induction therapy in newly diagnosed SLE patients with biopsy-proven LN.
Methods
We retrospectively studied eight consecutive patients with newly diagnosed SLE and LN who provided oral informed consent. The patients were treated at the Department of Internal Medicine, Himeji Red Cross Hospital, Himeji, Japan. All patients fulfilled the revised ACR criteria for SLE and had biopsy-proven LN. They received methylprednisolone pulse therapy i.v. (0.5 g/day for 3 days) at the beginning, followed by prednisolone orally. The daily dosage of prednisolone was started at 60 mg/day (80 mg/ day for patients weighing [60 kg) and then reduced by 10 mg/day every week to reach 30 mg/day, which was followed by further tapering by 5 mg/day at 2-week intervals until 20 mg/day was reached. Further tapering to 5 mg/day was allowed if the patient's condition was stable. The initial FK506 dosage was 3 mg/day once daily. Blood trough concentrations were measured at weeks 1, 2, 3, and 4 and months 2, 4, 5, and 6, and the dosage was titrated to maintain a blood concentration \10 ng/ml. Administration of MZB was initiated at 300 mg/day once daily for 3 days per week. Peak blood concentrations were measured if necessary, and the dosage (maximum 300 mg/day) was titrated to maintain an upper blood concentration of 1.0 lg/ml [20, 34] . When the patient showed complete SLE remission, either MZB or FK506 was stopped and another immunosuppressive agent was continued for maintenance therapy. The primary efficacy parameter was complete remission at 6 months, which was defined as proteinuria \0.2 g/day and normal serum creatinine level or no more than 15 % above the baseline value. A secondary efficacy parameter was SLE Disease Activity Index (SLEDAI) [35] remission at 6 months, which was defined as SLEDAI score of 0. Additional secondary efficacy parameters examined included proteinuria level, serum creatinine level, estimated glomerular filtration rate (eGFR), serum C3 level, anti-double-stranded DNA (anti-dsDNA) antibody titer, serum albumin level, hemoglobin level, and SLEDAI score. Therapeutic responses were determined at 2, 4, and 6 months. This study was approved by the ethical committee of our hospital.
Results
All patients were women, and their mean [standard deviation (SD)] age was 48.5 (20.3) years. At the start of treatment, all eight (100 %) patients had positive antidsDNA antibody titers, a mean (SD) serum creatinine level of 0.72 (0.4) mg/dl (range 0.33-1.55 mg/dl), and a mean (SD) daily proteinuria level of 4.56 (2.8) g (range 0.77-8.2 g). In addition, four (50.0 %) patients were nephrotic, four (50.0 %) were hypertensive, and one (12.5 %) had an elevated serum creatinine level at start of the treatment ( Table 1 ). The number of cases in the categories of the International Society of Nephrology (ISN)/Renal Pathology Society (RPS) 2003 criteria for LN classification were as follows: class II, one (12.5 %); class III, three (37.5 %); class IV-S, 0 (0 %); class IV-G, one (12.5 %); class V, three (37.5 %). After 6 months of therapy, complete remission and SLEDAI remission were achieved in seven (87.5 %) and three (37.5 %) patients, respectively (Fig. 1 ). Significant improvements in urine protein levels, C3 levels, and SLEDAI scores were observed in comparison with baseline values starting at month 2 ( Table 2 ; Fig. 2 ). The anti-dsDNA antibody titers at 6 months were normalized in seven (87.5 %) patients. MZB and FK506 were generally well tolerated in most cases, except three patients whose serum creatinine levels increased (Table 3) . However, all cases showed improvement with reduced doses of FK506.
Discussion
Renal involvement occurs in approximately 50 % of patients with SLE, and LN remains a predominant cause of morbidity and mortality. Therapeutic management of SLE is based on the type and severity of organ involvement. The ideal therapy for LN should induce an early response and remission, prevent flare-ups, have minimal adverse effects, and result in reductions in mortality and end-stage renal disease [36] . In this study, we found that a 6-month course of a combination therapy of MZB and FK506 with corticosteroids is a safe and effective treatment for patients with LN. The suitability of cyclophosphamide-based treatment regimens, which are the standard therapy for LN, remains a matter of debate, and alternative treatments are therefore required. In 2008, Bao et al. [33] reported the benefits of multitarget therapy (MMF and FK506 with corticosteroids) in cases of severe LN (class V ? IV). Multitarget therapy is possibly more effective for LN because SLE is an extremely heterogeneous disorder. The clinical use of MMF has not yet been approved, except for conditioning therapy before transplantation, by the Ministry of Health and Welfare in Japan. MZB is a purine synthesis inhibitor with similar activity to MMF, and we therefore used MZB instead of MMF to treat patients with LN. A correlation between peak MZB blood concentration and clinical response to the therapy has been observed in patients with LN [20] , and to ensure the peak concentration in our patients, we administered MZB 300 mg/day once daily for 3 days per week. MZB blood concentrations using this treatment protocol were above the target levels.
By month 12, complete remission and SLEDAI remission were achieved in eight (100 %) and five (62.5 %) patients, respectively. Even more surprisingly, microalbuminuria was normalized in five (62.5 %) patients (data not shown). With respect to the ultimate outcome of LN, patient survival rates at 10 years were reported to be 95 % for patients in complete remission, 76 % for patients in partial remission, and 41 % for patients with no remission [5] . Although complete remission in that study was defined as proteinuria level \0.33 g/day and serum creatinine level B1.4 mg/dl, we defined complete remission more strictly as normalization of proteinuria (\0.2 g/day) and serum creatinine levels. Considering patients directed to a treatment target, remission in both renal and serological parameters observed in our study will definitely lead to better outcomes. Remission rate (%) Fig. 1 Remission rates with the combination therapy. Complete remission defined as proteinuria level \0.2 g/day and normal serum creatinine level or B15 % above the baseline value. Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) remission was defined as a SLEDAI score of 0. The therapeutic responses were determined at 2, 4, and 6 months Owing to the long-term benefits, risks, and overall costs of the combination therapy, patients who showed SLEDAI remission after this combination therapy received maintenance therapy with one immunosuppressive agent. In a previous study, the occurrence of renal flare-ups was the strongest predictor of end-stage renal disease for patients who had once been in remission, and independent predictors of renal flare-ups were persistently low C3 levels despite the induction therapy and an absence of azathioprine maintenance therapy [12] . FK506 treatment may be related to a lower risk of lupus flare-up [25] , whereas beneficial effects of long-term treatment with MZB are also reported [19] . Therefore, both MZB and FK506 may be suitable as optional agents for LN maintenance treatment after this combination induction therapy. Furthermore, in comparison with conventional treatments performed at our hospital, combination therapy may contribute to a lower cumulative prednisolone dosage and a shorter duration of hospital stay (data not shown).
There are several limitations to this study. First, the sample size was small, and data were confined to 6 months. Further randomized controlled trials are needed to compare our multitarget regimen with standard regimens for LN. Second, although we recruited consecutive patients with a mean daily proteinuria level of 4.56 g, only four (50 %) patients had active proliferative LN. The sample size was too small to evaluate the therapeutic response in each type of biopsy-proven group. Third, urinary sediments were not included as a definition of treatment response because we considered that proteinuria normalization takes longer than that of urinary sediments. Fourth, it remains unclear which immunosuppressive agents should be chosen as the maintenance therapy for different types of LN. Finally, although the dosages of MZB and FK506 administered to our patients appeared to be well tolerated, their optimal dosage regimens remain unclear.
In summary, our findings suggest that the combined use of two well-tolerated immunosuppressive agents with different activities for LN induction therapy appears to be highly efficacious. Renal remission was induced by 6 months for almost all patients, who required a lower cumulative prednisolone dosage. This pilot induction regimen may be applied to various types of LN. Further studies are required to assess these expensive immunosuppressive agents in the treatment of LN. Physicians should thoroughly consider all possible benefits, theoretical risks, and overall costs of each treatment regimen in each individual to provide the best care for their patients.
